Introduction to the Growing Challenge of Drug Resistance

Multiple myeloma remains a significant hematological challenge for clinicians worldwide. While clinicians frequently prescribe immunomodulatory drugs as a cornerstone of treatment, many patients eventually encounter lenalidomide resistance in myeloma. This resistance often complicates long-term management and worsens the overall prognosis. However, a recent bibliometric analysis has mapped two decades of research to identify emerging hotspots and therapeutic strategies to overcome this hurdle.

Global Trends and Research Hotspots

The research landscape for myeloma has expanded rapidly over the last 20 years. Specifically, the United States, China, and Italy lead the global output of scientific publications. Institutions like Harvard University have established themselves as centers of excellence in this field. Furthermore, journals such as Blood continue to drive the discourse by publishing high-impact studies on resistance mechanisms. These publication trends reflect a global urgency to improve patient survival through better pharmacological interventions.

Identifying Hotspots in Lenalidomide Resistance in Myeloma

Researchers have identified four major clusters that dominate the current scientific literature. These clusters focus on combination therapies, cellular mechanisms, proteasome inhibitors, and monoclonal antibodies. Additionally, keyword burst analysis shows a growing focus on phase 3 trials and oral ixazomib. Recent studies highlight the role of signal transducer and activator of transcription 3 (STAT3) and nuclear factor kappa-B (NF-κB) pathways. Consequently, these pathways serve as vital targets for next-generation agents designed to bypass resistance. Clinicians are also moving toward evidence-based treatment consensus to standardize care in relapsed settings.

Future Directions for Clinical Practice

The field is evolving toward more personalized combination therapies. Moreover, scientists are exploring rational designs that target multiple pathways simultaneously. Since 2020, there has been a significant consensus on using open-label, multicenter studies to validate survival outcomes. Similarly, establishing clear guidelines for managing refractory cases will remain a priority for the global hematology community.

Frequently Asked Questions

What causes lenalidomide resistance in multiple myeloma?

Resistance typically develops through cellular mechanism changes, including alterations in the cereblon pathway and the activation of survival signaling pathways like NF-κB and STAT3.

How can clinicians manage patients who stop responding to lenalidomide?

Current strategies involve switching to proteasome inhibitors, monoclonal antibodies, or next-generation immunomodulatory agents, often within multicenter clinical trial frameworks.

Which institutions are leading the research in this field?

According to bibliometric data, Harvard University and other major centers in the USA and China are leading the research output and collaborations globally.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or establish a doctor-patient relationship. Refer to the latest local and national guidelines for clinical practice.

References

1. Li R et al. A bibliometric analysis of the research landscape of lenalidomide resistance in multiple myeloma. Discov Oncol. 2026 Jun 04. doi: 10.1007/s12672-026-05344-y. PMID: 42237042.

2. Terpos E et al. Management of relapsed and refractory multiple myeloma. Haematologica. 2021;106(6):1562-1573.

3. Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk-stratification, and management. Am J Hematol. 2022;97(8):1086-1107.